Por favor, use este identificador para citar o enlazar este ítem:
http://repositorio.pediatria.gob.mx:8180/handle/20.500.12103/2221
Título : | A randomized double-blind comparison of moxifloxacin and doxycycline/metronidazole/ciprofloxacin in the treatment of acute, uncomplicated pelvic inflammatory disease |
Creador: | Heystek M |
Nivel de acceso: | Open access |
Palabras clave : | Enfermedad Aguda - terapia - Adulto Antiinfecciosos - administración & dosificación - Adulto Antiinfecciosos - uso terapéutico - Adulto Compuestos Aza - administración & dosificación - Adulto Compuestos Aza - uso terapéutico - Adulto Ciprofloxacino - administración & dosificación - Adulto Ciprofloxacino - uso terapéutico - Adulto Método Doble Ciego - Adulto Doxiciclina - administración & dosificación - Adulto Doxiciclina - uso terapéutico - Adulto Esquema de Medicación - Adulto Quimioterapia Combinada - Adulto Femenina Metronidazol - administración & dosificación - Adulto- Adulto Metronidazol - uso terapéutico - Adulto Enfermedad Inflamatoria Pélvica - quimioterapia - Adulto Quinolinas - administración & dosificación - Adulto Quinolinas - uso terapéutico - Adulto Acute Disease - therapy - Adult Anti-Infective Agents - administration & dosage - Adult Anti-Infective Agents - therapeutic use - Adult Aza Compounds - administration & dosage - Adult Aza Compounds - therapeutic use - Adult Ciprofloxacin - administration & dosage - Adult Ciprofloxacin - therapeutic use - Adult Double-Blind Method Doxycycline - administration & dosage - Adult Doxycycline - therapeutic use - Adult Drug Administration Schedule - Adult Drug Therapy, Combination - Adult Female Metronidazole - administration & dosage - Adult Metronidazole - therapeutic use - Adult Pelvic Inflammatory Disease - drug therapy - Adult Quinolines - administration & dosage - Adult Quinolines - therapeutic use - Adult ciprofloxacin doxiciclina metronidazol moxifloxacin enfermedad pélvica inflammatory ciprofloxacin doxycycline metronidazole moxifloxacin pelvic inflammatory disease |
Descripción : | This multicentre, double-blind study was undertaken to demonstrate non-inferiority of once-daily oral moxifloxacin compared with combination therapy in the management of acute, uncomplicated pelvic inflammatory disease (PID). Women aged >or=18 years with PID were randomized to receive moxifloxacin (400 mg once daily) for 14 days or comparator treatment (doxycycline [100 mg twice daily] plus metronidazole [400 mg three times daily] for 14 days, plus one single 500-mg ciprofloxacin dose). Of the 434 valid per protocol (PP) patients, the overall clinical success rates at 2-14 days post-therapy were 96.6% (moxifloxacin) and 98.0% (comparator); moxifloxacin was non-inferior to the comparator regimen both in the PP (95% confidence interval [CI]: -4.5, 1.6) and intent-to-treat (95% CI: -5.8, 6.9) populations. Clinical success rates at 21-35 days post-therapy were 93.8% (166/177; data missing for 47 patients) for moxifloxacin and 91.3% (147/161; data missing for 37 patients) for the comparator. Bacteriological success rates at 2-14 days post-therapy were 92.5% (moxifloxacin) and 88.2% (comparator). Once-daily dosing and proven efficacy suggest that moxifloxacin may be of value in acute, uncomplicated PID |
Colaborador(es) u otros Autores: | Ross JD |
Fecha de publicación : | 2009 |
Tipo de publicación: | Artículo |
Formato: | |
Identificador del Recurso : | 10.1258/ijsa.2008.008495 |
Fuente: | International Journal of STD & AIDS. 20(10):690-5 |
URI : | http://repositorio.pediatria.gob.mx:8180/handle/20.500.12103/2221 |
Idioma: | eng |
Aparece en las colecciones: | Artículos |
Ficheros en este ítem:
No hay ficheros asociados a este ítem.
Los ítems de DSpace están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.